ABL1 and cancer: The discordance in c-Abl and p53 expression patterns may explain the lack of efficacy provided by Imatinib to patients harboring cancers of the breast [19–21], thyroid [61], and prostate [62–64], all of which represent tissues that normally co-express c-Abl and p53.